<!DOCTYPE html>
<html lang="en" data-arca>
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Cystic Fibrosis BRA â€” ArcaScience | CFTR Modulator Benefit-Risk Analysis</title>
  <meta name="description" content="AI-driven benefit-risk analysis for Cystic Fibrosis CFTR modulator therapy. Comprehensive BRA for elexacaftor/tezacaftor/ivacaftor (Trikafta), lumacaftor/ivacaftor, and next-generation CFTR correctors across genotype-specific populations.">

  <link rel="preload" href="/fonts/Inter-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="preload" href="/fonts/Literata-Variable.woff2" as="font" type="font/woff2" crossorigin>
  <link rel="stylesheet" href="/dist/arcascience-global.min.css">

  <script>
    (function(){
      if(window.matchMedia&&window.matchMedia('(prefers-reduced-motion: reduce)').matches){
        document.documentElement.classList.add('reduced-motion');
      }
    })();
  </script>
</head>
<body>

  <div data-scroll-progress></div>

  <!-- NAVIGATION -->
  <nav class="arca-nav" data-nav="sticky" role="navigation" aria-label="Main navigation">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px; display: flex; align-items: center; justify-content: space-between; height: 100%;">
      <a href="/" aria-label="ArcaScience home"><img src="/images/arcascience-logo.svg" alt="ArcaScience" height="32"></a>
      <div style="display: flex; align-items: center; gap: 32px;">
        <a href="/" class="arca-nav-link">Home</a>
        <div style="position: relative;"><a href="/platform-overview" class="arca-nav-link">Platform</a></div>
        <div style="position: relative;"><a href="/solution-therapeutic-area" class="arca-nav-link is-active">Solutions</a></div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/evidence-case-studies-hub" class="arca-nav-link">Evidence <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/evidence-case-studies-hub" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Case Studies</a>
            <a href="/evidence-publications" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Publications</a>
            <a href="/evidence-metrics" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Platform Metrics</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/about" class="arca-nav-link">Company <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; left: -12px; min-width: 200px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/about" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">About ArcaScience</a>
            <a href="/leadership" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Leadership</a>
            <a href="/careers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Careers</a>
            <a href="/science-methodology" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Science &amp; Methodology</a>
          </div>
        </div>
        <div style="position: relative;" class="arca-nav-dropdown-wrap">
          <a href="/resources" class="arca-nav-link">Resources <svg width="10" height="6" viewBox="0 0 10 6" fill="none" style="margin-left: 4px; vertical-align: middle;"><path d="M1 1L5 5L9 1" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></a>
          <div class="arca-nav-dropdown" style="position: absolute; top: 100%; right: -12px; min-width: 220px; padding: 8px 0; background: rgba(255,255,255,0.97); backdrop-filter: blur(12px); -webkit-backdrop-filter: blur(12px); border: 1px solid rgba(209,213,222,0.5); border-radius: 12px; box-shadow: 0 4px 12px rgba(0,0,0,0.06), 0 12px 32px rgba(0,0,0,0.08); opacity: 0; visibility: hidden; transform: translateY(-8px); transition: opacity 200ms ease, transform 200ms ease, visibility 200ms; z-index: 100;">
            <a href="/resources" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Resource Hub</a>
            <a href="/resources-whitepapers" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Whitepapers</a>
            <a href="/resources-webinars" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Webinars &amp; Events</a>
            <div style="height: 1px; background: linear-gradient(90deg, transparent, rgba(35,86,160,0.15), transparent); margin: 6px 12px;"></div>
            <a href="/resources-faq" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">FAQ</a>
            <a href="/resources-glossary" style="display: block; padding: 8px 16px; font-size: 0.875rem; color: var(--grey-800); text-decoration: none; border-radius: 6px; margin: 0 4px;">Glossary</a>
          </div>
        </div>
      </div>
      <a href="/contact" class="arca-btn-primary" style="height: 40px; padding: 8px 24px; font-size: 0.875rem;">Talk to a Scientist</a>
    </div>
  </nav>

  <div style="height: var(--nav-height);"></div>

  <main role="main">

    <!-- HERO -->
    <section class="arca-bg-blue-900" style="position: relative; overflow: hidden; padding: var(--space-8) 0 var(--space-9);" data-animate>
      <div style="position: absolute; top: -100px; right: -100px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(13, 124, 107, 0.12) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 8s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -80px; left: -80px; width: 400px; height: 400px; background: radial-gradient(circle, rgba(59, 125, 216, 0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(60px); pointer-events: none; animation: as-float 10s ease-in-out infinite reverse; z-index: 0;"></div>

      <svg width="420" height="320" viewBox="0 0 420 320" fill="none" aria-hidden="true" style="position: absolute; right: -20px; top: 50%; transform: translateY(-50%); opacity: 0.12; pointer-events: none; z-index: 0;">
        <circle cx="210" cy="160" r="16" stroke="rgba(13,124,107,0.5)" stroke-width="1.5" fill="none"/>
        <circle cx="210" cy="160" r="6" fill="rgba(13,124,107,0.3)"/>
        <circle cx="290" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="100" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="290" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <circle cx="130" cy="220" r="10" stroke="rgba(13,124,107,0.4)" stroke-width="1" fill="none"/>
        <line x1="210" y1="160" x2="290" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="100" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="290" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
        <line x1="210" y1="160" x2="130" y2="220" stroke="rgba(13,124,107,0.3)" stroke-width="1.5"/>
      </svg>

      <div style="position: relative; z-index: 1; max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <nav aria-label="Breadcrumb" style="margin-bottom: var(--space-5);">
          <ol style="list-style: none; padding: 0; margin: 0; display: flex; align-items: center; gap: 8px; font-size: 0.75rem;">
            <li><a href="/" style="color: rgba(255,255,255,0.65); text-decoration: none;">Home</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none;">Therapeutic Areas</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li><a href="/ta-rare-diseases" style="color: rgba(255,255,255,0.65); text-decoration: none;">Rare Diseases</a></li>
            <li style="color: rgba(255,255,255,0.4);">/</li>
            <li style="color: var(--white);">Cystic Fibrosis</li>
          </ol>
        </nav>

        <div style="max-width: 820px;">
          <p class="arca-label arca-text-blue-400" style="margin-bottom: var(--space-3);">Rare Diseases &rsaquo; Cystic Fibrosis</p>
          <h1 class="arca-display-lg arca-text-white" style="margin-bottom: var(--space-5);">
            CFTR Modulator Benefit-Risk Analysis for Cystic Fibrosis
          </h1>
          <p class="arca-body-lg" style="color: rgba(255,255,255,0.85); max-width: 680px; margin-bottom: var(--space-7);">
            CFTR modulator therapy &mdash; led by elexacaftor/tezacaftor/ivacaftor (Trikafta) &mdash; has transformed cystic fibrosis from a fatal childhood disease to a chronic condition with near-normal life expectancy for many patients. ArcaScience provides comprehensive BRA across CFTR modulator combinations, genotype-specific efficacy modeling, and the emerging safety challenges of a CF population now surviving into middle age.
          </p>
          <div style="display: flex; gap: 16px; flex-wrap: wrap;">
            <a href="/platform-overview" class="arca-btn-primary-inverted">See Platform</a>
            <a href="/contact?disease=cystic-fibrosis" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Request Demo</a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY STATISTICS -->
    <section class="arca-credibility-bar" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="100000" data-countup-suffix="+">0</span>
            <p class="arca-caption">People living with CF worldwide</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="90" data-countup-suffix="%">0</span>
            <p class="arca-caption">CF patients eligible for Trikafta (at least one F508del allele)</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="14" data-countup-suffix=" ppFEV1">0</span>
            <p class="arca-caption">Mean improvement in lung function with Trikafta (VX-445 Phase 3)</p>
          </div>
          <div class="arca-credibility-metric">
            <span class="arca-stat-lg" data-countup="680" data-countup-suffix="+">0</span>
            <p class="arca-caption">CF CFTR modulator trials analyzed</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DISEASE OVERVIEW -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Disease Overview</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-5);">Why CFTR Modulator Therapy Demands Specialized BRA</h2>
          <p class="arca-body-lg arca-text-grey-600">
            Cystic fibrosis CFTR modulator therapy presents unique benefit-risk challenges: genotype-dependent efficacy requiring mutation-specific BRA, hepatotoxicity monitoring in a population already prone to CF-related liver disease, significant CYP3A-mediated drug-drug interactions, and entirely new clinical questions around pregnancy, mental health, and long-term organ effects in a patient population that was never expected to survive to adulthood.
          </p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Hepatotoxicity &amp; Drug-Drug Interactions</h3>
            <p class="arca-body-sm arca-text-grey-600">
              CFTR modulators carry hepatotoxicity risk with ALT/AST elevations reported in 5-8% of patients on Trikafta, complicated by pre-existing CF-related liver disease in up to 30% of patients. All CFTR modulators are CYP3A substrates, creating significant drug-drug interaction risk with azole antifungals (commonly used for allergic bronchopulmonary aspergillosis), certain antibiotics, and hormonal contraceptives. BRA must model the cumulative hepatic burden and interaction potential across the complex CF polypharmacy landscape.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Genotype-Specific Efficacy Variation</h3>
            <p class="arca-body-sm arca-text-grey-600">
              CFTR modulator efficacy varies dramatically by genotype. Trikafta covers approximately 90% of CF patients (those with at least one F508del allele), but patients with minimal function mutations, splice mutations, or rare genotypes may have reduced or absent response. Ivacaftor monotherapy (Kalydeco) targets gating mutations (G551D and others) present in only ~5% of patients. BRA must incorporate genotype-stratified efficacy data from VX-445 Phase 3, EVOLVE, TRANSPORT trials and real-world evidence to support genotype-specific labeling and reimbursement decisions.
            </p>
          </div>
          <div class="arca-card" data-animate="slide-up">
            <h3 class="arca-heading-3" style="margin-bottom: var(--space-3);">Emerging Long-Term Survival Challenges</h3>
            <p class="arca-body-sm arca-text-grey-600">
              With Trikafta dramatically improving lung function and projected median survival now exceeding 50 years, entirely new BRA challenges are emerging. Adolescent and young adult mental health issues (depression, anxiety, identity adjustment) are increasingly reported. Pregnancy in CF patients on CFTR modulators raises teratogenicity questions with limited data. Pediatric cataracts have been observed with ivacaftor-containing regimens, requiring ophthalmologic monitoring. These long-term safety signals require novel pharmacovigilance approaches for a population with no historical precedent for extended survival.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ARCASCIENCE APPROACH -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-grey-50 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">Platform Capabilities</p>
          <h2 class="arca-display-sm" style="margin-bottom: var(--space-4);">How ArcaScience Addresses CF BRA</h2>
          <p class="arca-body-lg arca-text-grey-600" style="max-width: 680px; margin: 0 auto;">Our modules are configured with CF-specific CFTR modulator data, genotype-stratified efficacy models, hepatotoxicity monitoring algorithms, and regulatory templates for rare disease submissions with genotype-dependent labeling.</p>
        </div>

        <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 24px;">
          <div class="arca-card arca-card-colored-top is-data" data-animate="slide-up">
            <span class="arca-module-tag is-data">Data Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">CF CFTR Modulator Data</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">680+ CF clinical trials including VX-445 Phase 3 (Trikafta pivotal), EVOLVE, TRANSPORT (tezacaftor/ivacaftor), and STRIVE/ENVISION (ivacaftor monotherapy). Integrated CF Foundation Patient Registry data, real-world evidence from Trikafta post-marketing surveillance, and genotype-phenotype correlation databases covering 2,000+ CFTR mutations. Drug-drug interaction databases mapped to common CF co-medications.</p>
            <a href="/platform-data-intelligence" class="arca-btn-tertiary">Explore Data Engine <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-card arca-card-colored-top is-analytics" data-animate="slide-up">
            <span class="arca-module-tag is-analytics">Decision Intelligence</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">Genotype-Stratified BRA Models</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">AI models for genotype-specific CFTR modulator response prediction, hepatotoxicity risk scoring incorporating baseline liver function and CYP3A inhibitor co-administration, pulmonary exacerbation rate modeling (ppFEV1 trajectories), drug-drug interaction severity estimation, and pediatric cataract risk stratification for ivacaftor-containing regimens in patients under 12 years of age.</p>
            <a href="/platform-ai-models" class="arca-btn-tertiary">Explore AI Models <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-card arca-card-colored-top is-output" data-animate="slide-up">
            <span class="arca-module-tag is-output">Automated Outputs</span>
            <h3 class="arca-heading-2" style="margin: var(--space-4) 0 var(--space-3);">CF Regulatory Outputs</h3>
            <p class="arca-body-sm arca-text-grey-600" style="margin-bottom: var(--space-5);">PSURs with genotype-stratified safety and efficacy analysis, RMPs incorporating hepatotoxicity monitoring protocols and CYP3A drug interaction management guidelines, label extension support for new genotype populations, pregnancy exposure registry reports, and pediatric ophthalmologic monitoring frameworks. Templates aligned with FDA rare disease and EMA orphan medicinal product regulatory pathways.</p>
            <a href="/platform-outputs" class="arca-btn-tertiary">Explore Outputs <span class="arca-arrow">&rarr;</span></a>
          </div>
        </div>
      </div>
    </section>

    <!-- KEY METRICS -->
    <section class="arca-bg-blue-50 arca-bg-mesh" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="text-align: center; margin-bottom: var(--space-8);">
          <p class="arca-section-label">CF Intelligence</p>
          <h2 class="arca-display-sm">Platform Performance in Cystic Fibrosis</h2>
        </div>
        <div style="display: grid; grid-template-columns: repeat(4, 1fr); gap: 32px; text-align: center;">
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="2400000000" data-countup-suffix="+">0</span>
            <p class="arca-caption arca-text-grey-600">CF safety &amp; efficacy data points tracked</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="65" data-countup-suffix="%">0</span>
            <p class="arca-caption arca-text-grey-600">Faster hepatotoxicity signal detection in CF patients</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="2000" data-countup-suffix="+">0</span>
            <p class="arca-caption arca-text-grey-600">CFTR mutations mapped with modulator response data</p>
          </div>
          <div>
            <span class="arca-stat-lg" style="color: var(--indigo-600);" data-countup="5">0</span>
            <p class="arca-caption arca-text-grey-600">CF regulatory submissions supported globally</p>
          </div>
        </div>
      </div>
    </section>

    <!-- CASE EVIDENCE -->
    <section style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 64px; align-items: center;">
          <div>
            <p class="arca-section-label">Case Evidence &mdash; Cystic Fibrosis</p>
            <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">Genotype-Stratified BRA for CFTR Modulator Label Extension</h2>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Challenge</h3>
              <p class="arca-body-sm arca-text-grey-600">A CFTR modulator manufacturer sought to extend their label to cover additional rare CFTR genotypes beyond the original F508del homozygous and heterozygous populations. The challenge required demonstrating benefit-risk across genotype subgroups with very small patient numbers (some mutations present in fewer than 50 patients globally), while simultaneously managing hepatotoxicity monitoring in patients with pre-existing CF liver disease.</p>
            </div>
            <div style="margin-bottom: var(--space-5);">
              <h3 class="arca-heading-4" style="margin-bottom: var(--space-2); color: var(--indigo-600);">Result</h3>
              <p class="arca-body-sm arca-text-grey-600">ArcaScience's genotype-stratified models integrated in vitro CFTR function assays, clinical trial data, and real-world evidence from CF Foundation Registry to build mutation-specific benefit-risk profiles. The AI identified a hepatotoxicity risk enrichment in patients with pre-existing CF-related liver disease co-administered CYP3A inhibitors, enabling proactive dosing guidance. The label extension was approved covering 26 additional rare mutations.</p>
            </div>
            <div style="display: grid; grid-template-columns: repeat(2, 1fr); gap: 24px; margin-bottom: var(--space-6);">
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="26" data-countup-suffix="">0</span>
                <p class="arca-caption arca-text-grey-600">Additional CFTR mutations approved for label extension</p>
              </div>
              <div>
                <span class="arca-stat-sm" style="color: var(--indigo-600);" data-countup="58" data-countup-suffix="%">0</span>
                <p class="arca-caption arca-text-grey-600">Reduction in time to genotype-specific BRA completion</p>
              </div>
            </div>
            <a href="/evidence-case-studies-hub" class="arca-btn-tertiary">View All Case Studies <span class="arca-arrow">&rarr;</span></a>
          </div>
          <div class="arca-testimonial" style="text-align: left;">
            <div class="arca-testimonial-quote" style="padding-left: 24px; border-left: 3px solid var(--blue-400);">
              Extending our label to rare CFTR genotypes was previously considered infeasible due to tiny patient numbers. ArcaScience's approach of integrating in vitro functional data with clinical and registry evidence created a genotype-specific BRA framework that the FDA accepted as sufficient for approval. That opened treatment access for thousands of patients who had no CFTR modulator option.
            </div>
            <div class="arca-testimonial-attribution" style="margin-top: var(--space-5);">
              <p class="arca-body-md" style="font-weight: 600;">Director of CF Clinical Development</p>
              <p class="arca-body-sm arca-text-grey-600">Specialty Pharma Company</p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- FAQ ACCORDION -->
    <div class="arca-section-divider" aria-hidden="true"></div>

    <section class="arca-bg-teal-100 arca-bg-rings" style="padding: var(--space-9) 0;" data-animate>
      <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
        <div style="max-width: 720px; margin: 0 auto 48px; text-align: center;">
          <p class="arca-section-label">Frequently Asked Questions</p>
          <h2 class="arca-display-sm">Cystic Fibrosis CFTR Modulator BRA</h2>
        </div>
        <div style="max-width: 820px; margin: 0 auto;">
          <div class="arca-accordion" data-accordion="group">
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience handle genotype-specific CFTR modulator BRA?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Our platform integrates three evidence layers for genotype-specific BRA: (1) in vitro CFTR function data from cell-based assays measuring chloride transport rescue for individual mutations, (2) clinical trial efficacy data stratified by genotype from VX-445 Phase 3, EVOLVE, TRANSPORT, and STRIVE trials, and (3) real-world evidence from CF Foundation Patient Registry and international registries. AI models correlate in vitro CFTR rescue levels with clinical ppFEV1 improvement and sweat chloride reduction, enabling benefit-risk estimation even for ultra-rare mutations with minimal clinical data.</p>
              </div>
            </div>
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Can the platform model CYP3A drug-drug interactions in CF patients?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Yes. CFTR modulators are CYP3A substrates, and CF patients frequently require co-medications that are strong CYP3A inhibitors (itraconazole, voriconazole for ABPA) or inducers (rifampin for NTM infections). Our AI models integrate pharmacokinetic data, clinical drug interaction studies, and real-world co-prescription patterns to quantify interaction severity, predict dose adjustment needs, and flag high-risk combinations. This includes modeling the impact of hepatic impairment (common in CF) on CYP3A metabolism capacity, which amplifies interaction risk beyond what healthy-volunteer PK studies predict.</p>
              </div>
            </div>
            <div class="arca-accordion-item" style="border-bottom: 1px solid var(--grey-200);">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">How does ArcaScience address pregnancy safety in CF patients on modulators?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Pregnancy in CF patients on CFTR modulators is a rapidly emerging clinical reality &mdash; historically, few women with CF survived to reproductive age or had sufficient health to conceive. Our platform aggregates pregnancy exposure registry data, preclinical reproductive toxicology findings, and emerging real-world pregnancy outcomes from CF Foundation and international registries. BRA models weigh the risk of CFTR modulator exposure during pregnancy against the documented maternal lung function decline when modulators are discontinued. This supports regulatory pregnancy category decisions and clinical guidance development.</p>
              </div>
            </div>
            <div class="arca-accordion-item">
              <button class="arca-accordion-header" style="width: 100%; text-align: left; padding: var(--space-5) 0; display: flex; justify-content: space-between; align-items: center; background: none; border: none; cursor: pointer;">
                <h3 class="arca-heading-3">Does the platform monitor pediatric cataract risk with ivacaftor?</h3>
                <span class="arca-accordion-icon" style="color: var(--grey-500); font-size: 1.25rem;">+</span>
              </button>
              <div class="arca-accordion-content" style="padding: 0 0 var(--space-5); display: none;">
                <p class="arca-body-sm arca-text-grey-600">Yes. Non-congenital lens opacities and cataracts have been reported in pediatric patients receiving ivacaftor-containing regimens, including Trikafta. Our platform tracks ophthalmologic safety signals from clinical trials, post-marketing reports, and CF registry data. AI models assess age-at-exposure risk stratification, cumulative dose-response relationships, and comparative rates across ivacaftor-containing vs. non-ivacaftor CFTR modulator regimens. This supports baseline and periodic ophthalmologic examination recommendations in the label and risk management plan, particularly for patients initiating treatment before age 12.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- CTA -->
    <section class="arca-cta-section" data-animate style="position: relative; overflow: hidden;">
      <div style="position: absolute; top: -60px; left: -60px; width: 300px; height: 300px; background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 7s ease-in-out infinite; z-index: 0;"></div>
      <div style="position: absolute; bottom: -40px; right: -40px; width: 250px; height: 250px; background: radial-gradient(circle, rgba(255,255,255,0.06) 0%, transparent 70%); border-radius: 50%; filter: blur(40px); pointer-events: none; animation: as-float 9s ease-in-out infinite reverse; z-index: 0;"></div>
      <div style="position: relative; z-index: 1; max-width: 680px; margin: 0 auto; padding: 0 24px;">
        <h2 class="arca-heading-1" style="margin-bottom: var(--space-5);">See ArcaScience Applied to Cystic Fibrosis</h2>
        <p class="arca-body-lg" style="margin-bottom: var(--space-7);">Request a demonstration focused on CF CFTR modulator BRA. Our rare disease scientists will present genotype-stratified efficacy models, hepatotoxicity and drug interaction risk frameworks, and long-term safety surveillance approaches for the expanding CF patient population.</p>
        <div style="display: flex; gap: 16px; justify-content: center; flex-wrap: wrap;">
          <a href="/contact?disease=cystic-fibrosis" class="arca-btn-primary-inverted">Request CF Briefing</a>
          <a href="/platform-overview" class="arca-btn-secondary" style="border-color: rgba(255,255,255,0.3); color: var(--white);">Explore the Platform <span class="arca-arrow">&rarr;</span></a>
        </div>
      </div>
    </section>

  </main>

  <!-- FOOTER -->
  <footer class="arca-bg-blue-900" style="padding: var(--space-9) 0 var(--space-7);">
    <div style="max-width: var(--content-max-width); margin: 0 auto; padding: 0 24px;">
      <div style="display: grid; grid-template-columns: 2fr 1fr 1fr 1fr 1fr; gap: 48px;">
        <div><img src="/images/arcascience-logo-white.svg" alt="ArcaScience" height="28" style="margin-bottom: var(--space-5);"><p class="arca-body-sm" style="color: rgba(255,255,255,0.65); max-width: 280px;">AI-driven benefit-risk analysis for pharmaceutical development. Founded 2018.</p></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Platform</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/platform-overview" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Overview</a><a href="/platform-data-intelligence" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Data Intelligence</a><a href="/platform-ai-models" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Decision Intelligence</a><a href="/platform-outputs" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Regulatory Outputs</a><a href="/security-compliance" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Security & Compliance</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Solutions</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/solution-early-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Early Development</a><a href="/solution-late-development" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Late Development</a><a href="/solution-post-marketing" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Post-Marketing</a><a href="/solution-therapeutic-area" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Therapeutic Areas</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Company</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">About</a><a href="/leadership" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Team</a><a href="/careers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Careers</a><a href="/about" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">News</a><a href="/contact" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Contact</a></nav></div>
        <div><p class="arca-label" style="color: rgba(255,255,255,0.45); margin-bottom: var(--space-4);">Resources</p><nav style="display: flex; flex-direction: column; gap: 12px;"><a href="/evidence-case-studies-hub" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Case Studies</a><a href="/resources-whitepapers" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Whitepapers</a><a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Blog</a><a href="/resources" style="color: rgba(255,255,255,0.65); text-decoration: none; font-size: 0.875rem;">Documentation</a></nav></div>
      </div>
      <div style="margin-top: var(--space-8); padding-top: var(--space-5); border-top: 1px solid rgba(255,255,255,0.1); display: flex; justify-content: space-between; align-items: center;">
        <p class="arca-caption" style="color: rgba(255,255,255,0.45);">&copy; 2026 ArcaScience. All rights reserved.</p>
        <div style="display: flex; gap: 24px;">
          <a href="/legal-privacy" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Privacy</a>
          <a href="/legal-terms" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Terms</a>
          <a href="/legal-cookies" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Cookies</a>
          <a href="/legal-accessibility" style="color: rgba(255,255,255,0.45); text-decoration: none; font-size: 0.75rem;">Accessibility</a>
        </div>
      </div>
    </div>
  </footer>

  <button data-back-to-top aria-label="Back to top"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><path d="M8 12V4M4 7l4-4 4 4" stroke="currentColor" stroke-width="1.5" stroke-linecap="round"/></svg></button>

  <script src="/dist/arcascience-global.min.js" defer></script>
  <script src="/dist/arcascience-countup.min.js" defer></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      if (window.ArcaScience) ArcaScience.init();
      if (window.ArcaScienceCountUp) ArcaScienceCountUp.init({ selector: '[data-countup]' });
      document.querySelectorAll('[data-accordion] .arca-accordion-header').forEach(function(header) {
        header.addEventListener('click', function() {
          var content = this.nextElementSibling;
          var icon = this.querySelector('.arca-accordion-icon');
          var isOpen = content.style.display === 'block';
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-content').forEach(function(c) { c.style.display = 'none'; });
          this.closest('[data-accordion]').querySelectorAll('.arca-accordion-icon').forEach(function(i) { i.textContent = '+'; });
          if (!isOpen) { content.style.display = 'block'; icon.textContent = '\u2212'; }
        });
      });
    });
  </script>
</body>
</html>